TY - JOUR
T1 - Apo A-I modulating therapies
AU - Nicholls, Stephen J.
N1 - Funding Information:
Disclosure Conflicts of interest: S.J. Nicholls: has been a consultant for Roche, Merck, Sanofi-Aventis, Omthera, AstraZeneca, and Pfizer; and has received grant support from AstraZeneca, Eli Lilly, Resverlo-gix, Anthera, Roche, and Novartis.
PY - 2011/12
Y1 - 2011/12
N2 - The substantial residual risk of cardiovascular events despite the implementation of effective lowering of low-density lipoprotein cholesterol highlights the need to develop additional cardioprotective therapies. Evidence from population and animal studies suggests that high-density lipoproteins (HDLs), the protective lipid particles, may represent a target for therapeutic modification. As a result intensive efforts are in progress to develop new agents that promote HDL activity. Among these different approaches, a range of strategies that target apolipoprotein A-I, the major protein carried on HDL, are being evaluated.
AB - The substantial residual risk of cardiovascular events despite the implementation of effective lowering of low-density lipoprotein cholesterol highlights the need to develop additional cardioprotective therapies. Evidence from population and animal studies suggests that high-density lipoproteins (HDLs), the protective lipid particles, may represent a target for therapeutic modification. As a result intensive efforts are in progress to develop new agents that promote HDL activity. Among these different approaches, a range of strategies that target apolipoprotein A-I, the major protein carried on HDL, are being evaluated.
KW - Apolipoprotein A-I
KW - Atherosclerosis
KW - Coronary artery disease
KW - High-density lipoproteins
KW - Lipids
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=81255158515&partnerID=8YFLogxK
U2 - 10.1007/s11886-011-0223-0
DO - 10.1007/s11886-011-0223-0
M3 - Article
C2 - 21947768
AN - SCOPUS:81255158515
SN - 1523-3782
VL - 13
SP - 537
EP - 543
JO - Current Cardiology Reports
JF - Current Cardiology Reports
IS - 6
ER -